1

Grifols

#2411

Rank

$5.99B

Marketcap

ES Spain

Country

Grifols
Leadership team

Mr. Raimon Grifols Roura (Co-CEO & Exec. Director)

Mr. Steven Francis Mayer J.D. (Exec. Chairman)

Mr. Víctor Grifols Deu (Co-CEO & Exec. Director)

Products/ Services
Biotechnology, Health Care, Manufacturing
Number of Employees
20,000 - 50,000
Headquarters
Barcelona, Catalonia, Spain
Established
1940
Company Registration
SEC CIK number: 0001438569
Net Income
500M - 1B
Revenue
Above - 1B
Traded as
GRFS
Social Media
Overview
Location
Summary
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum?from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring?to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
History

Grifols' origin lies in the laboratory founded in 1940 in Barcelona by Dr Josep A. Grífols Roig, a hematologist and scientist . His son, Dr Josep A. Grifols Lucas was the first researcher to publish the plasmapheresis procedure in 1952. The company introduced its liquid IVIG product into the European market in the mid-1990s.

Probitas Pharma, S.A. was incorporated with high limited liability under Spanish law on 22 June 1987; on 27 June 2005 the company changed its name to Grifols, S.A. In 2003 the company acquired certain assets of the Los Angeles-based Alpha Therapeutic as the basis of its American expansion. On May 17, 2006, Grifols securities were listed on Spain's Mercado Continuo.In 2009, CSL Limited attempted to takeover Talecris Biotherapeutics for $3,1 billion but was stopped by the Federal Trade Commission. On June 1, 2011, a year after announcing the $4 billion deal, Grifols completed a takeover of Talecris Biotherapeutics, headquartered in Research Triangle Park in North Carolina, with over 2000 employees.Grifols acquired the blood transfusion diagnostics unit from Novartis in 2013 as a "platform for global expansion". This unit is based in Emeryville, California and was a part of Chiron acquired by Novartis in 2006.In 2015, the company acquired a 45% stake in Alkahest as part of planned co-development of "plasma-based products for the treatment of cognitive decline in aging and disorders of the CNS, including Alzheimer's." In 2020 Grifols acquired the remaining stock of Alkahest “bringing its ownership of Alkahest to 100%”.In December 2016, Grifols acquired Hologics interest in their existing joint blood screening unit for $1.85 billion

Mission
Our mission is to improve the health and well-being of patients around the world.
Vision
We strive to be a global leader in our markets and a constant industry reference for innovation, quality and safety.
Key Team

Mr. Alfredo Arroyo Guerra (CFO & VP)

Mrs. Eva Bastida Tubau (Corp. VP and Director of Scientific & Medical Affairs)

Ms. Nuria Pascual Lapeña (VP of Corp. Treasury, Risk Management Investor Relation & Sustainability Officer)

Mr. David Ian Bell (Gen. Counsel & Chief Corp. Devel. Officer)

Mr. Mateo Florencio Borrás Humbert (Corp. VP & Chief HR Officer)

Ms. Maria Teresa-Rioné Llano (Chief Communications Officer)

Ms. Montserrat Gaja Llamas (Chief HR Officer)

Recognition and Awards
Grifols has been recognized with numerous awards. These include a Global Award for Excellence in Corporate Social Responsibility, a Corporate Market Leadership Award from Frost & Sullivan, and the S&P Global Industry Leader Award.
References
Grifols
Leadership team

Mr. Raimon Grifols Roura (Co-CEO & Exec. Director)

Mr. Steven Francis Mayer J.D. (Exec. Chairman)

Mr. Víctor Grifols Deu (Co-CEO & Exec. Director)

Products/ Services
Biotechnology, Health Care, Manufacturing
Number of Employees
20,000 - 50,000
Headquarters
Barcelona, Catalonia, Spain
Established
1940
Company Registration
SEC CIK number: 0001438569
Net Income
500M - 1B
Revenue
Above - 1B
Traded as
GRFS
Social Media